keyword
MENU ▼
Read by QxMD icon Read
search

Avastin

keyword
https://www.readbyqxmd.com/read/28301412/large-silicone-droplets-after-intravitreal-bevacizumab-avastin
#1
Robert L Avery, Alessandro A Castellarin, Dilsher S Dhoot, Dante J Pieramici, Maʼan A Nasir, Nathan C Steinle, Logan P Avery, Gabriel M Gordon
PURPOSE: Despite its off-label status, intravitreal bevacizumab is the most commonly used intraocular anti-vascular endothelial growth factor agent. Regulation of compounding pharmacies has recently increased to make compounded pharmaceuticals safer. Despite these changes, a marked increase in symptomatic, large silicone oil droplets following intravitreal bevacizumab injections was noticed. METHODS: Retrospective chart review was performed. Within a single private practice, patients who were noted to have large or symptomatic silicone oil bubbles after an intravitreal injection were reviewed...
March 15, 2017: Retinal Cases & Brief Reports
https://www.readbyqxmd.com/read/28297041/fluorescein-angiography-versus-optical-coherence-tomography-angiography-in-macular-telangiectasia-type-i-treated-with-bevacizumab-therapy
#2
Nicolas A Yannuzzi, Ninel Z Gregori, Luiz Roisman, Nisha Gupta, Brian E Goldhagen, Raquel Goldhardt
This is a report of microvascular changes seen on fluorescein angiography (FA) and optical coherence tomography angiography (OCTA) in a 47-year-old man with macular telangiectasia Type 1 (MacTel1) after a 7-year bevacizumab (Avastin; Genentech, South San Francisco, CA) treatment course. OCTA allowed for clear visualization of most telangiectasias and aneurysms in the deep capillary plexus, with only few microvascular dilatations in the superficial plexus. In addition, areas of capillary dropout in the superficial and deep vascular plexa located near telangiectasias were documented on OCTA...
March 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/28297035/short-term-effects-of-early-switching-to-ranibizumab-or-aflibercept-in-diabetic-macular-edema-cases-with-non-response-to-bevacizumab
#3
Mohammed Ashraf, Ahmed A R Souka, Hassan ElKayal
BACKGROUND AND OBJECTIVES: To study the effect of early switching to ranibizumab (Lucentis; Genentech, South San Francisco, CA) or aflibercept (Eylea; Regeneron, Tarrytown, NY) in cases of diabetic macular edema (DME) that have shown no response to bevacizumab (Avastin; Genentech, South San Francisco, CA). PATIENTS AND METHODS: A retrospective study involving 59 eyes of 45 patients with DME previously treated with bevacizumab. Patients were switched either to ranibizumab or aflibercept...
March 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/28294622/tracking-antibody-distribution-with-near-infrared-fluorescent-dyes-impact-of-dye-structure-and-degree-of-labeling-on-plasma-clearance
#4
Cornelius Cilliers, Ian Nessler, Nikolas Christodolu, Greg M Thurber
Monoclonal antibodies labeled with near infrared (NIR) fluorophores have potential use in disease detection, intraoperative imaging, and pharmacokinetic characterization of therapeutic antibodies in both the preclinical and clinical setting. Recent work has shown conjugation of NIR fluorophores to antibodies can potentially alter antibody disposition at a sufficiently high degree of labeling (DoL); however, other reports show minimal impact after labeling with NIR fluorophores. In this work, we label two clinically approved antibodies Herceptin (trastuzumab) and Avastin (bevacizumab) with NIR dyes IRDye 800CW (800CW) or Alexa Fluor 680 (AF680), at 1...
March 15, 2017: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/28256268/antiangiogenic-activity-of-a-bevacizumab-loaded-polyurethane-device-in-animal-neovascularization-models
#5
A E R Ferreira, B F M Castro, L C Vieira, G D Cassali, C M Souza, G O Fulgêncio, E Ayres, R L Oréfice, R Jorge, A Silva-Cunha, S L Fialho
PURPOSE: To evaluate the antiangiogenic activity of bevacizumab-loaded polyurethane using two animal models of neovascularization. METHODS: The percentage of blood vessels was evaluated in a chicken chorioallantoic membrane model (n=42) and in the rabbit cornea (n=24) with neovascularization induced by alkali injury. In each model, the animals were randomly divided into the groups treated with the bevacizumab-loaded polyurethane device, phosphate-buffered-saline (negative control) and bevacizumab commercial solution (positive control)...
February 27, 2017: Journal Français D'ophtalmologie
https://www.readbyqxmd.com/read/28238523/posterior-reversible-encephalopathy-syndrome-pres-with-sub-arachnoid-haemorrhage-after-bevacizumab-and-5-fu
#6
Jennifer Massey
PRES is a neurological syndrome characterised by reversible subcortical vasogenic brain oedema in patients with acute neurological signs and symptoms. It occurs in the context of fluctuations in blood pressure, renal failure, autoimmune disorders, eclamptic syndromes and with use of cytotoxic drugs. We present the case of a 60year old female with advanced bowel cancer who was admitted with seizures and sub-arachnoid haemorrhage, with radiographic features of PRES, shortly after receiving bevacizumab (Avastin), a VEGF-inhibitor...
February 23, 2017: Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia
https://www.readbyqxmd.com/read/28194878/platelet-activated-serum-might-have-a-therapeutic-effect-on-damaged-articular-cartilage
#7
Munetaka Yokoyama, Masato Sato, Yoshiki Tani, Miyuki Yokoyama, Mami Kokubo, Masayuki Yamato, Teruo Okano, Joji Mochida
Platelet-activated serum (PAS) was collected from rabbits. This contains high concentrations of growth factors, including vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF)-BB, and transforming growth factor-beta (TGF-β). PAS was injected into the knee joints of Japanese White rabbits subjected to anterior cruciate ligament transection (ACL-T) to investigate its therapeutic effects on articular cartilage. The effect of Avastin (an anti-VEGF monoclonal antibody) on VEGF expression was also investigated...
February 14, 2017: Journal of Tissue Engineering and Regenerative Medicine
https://www.readbyqxmd.com/read/28193603/roche-asks-who-to-remove-avastin-from-essential-medicines-list
#8
Deborah Cohen
No abstract text is available yet for this article.
February 13, 2017: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/28117563/patent-law-s-reproducibility-paradox
#9
Jacob S Sherkow
Clinical research faces a reproducibility crisis. Many recent clinical and preclinical studies appear to be irreproducible--their results cannot be verified by outside researchers. This is problematic for not only scientific reasons but also legal ones: patents grounded in irreproducible research appear to fail their constitutional bargain of property rights in exchange for working disclosures of inventions. The culprit is likely patent law’s doctrine of enablement. Although the doctrine requires patents to enable others to make and use their claimed inventions, current difficulties in applying the doctrine hamper or even actively dissuade reproducible data in patents...
January 2017: Duke Law Journal
https://www.readbyqxmd.com/read/28048647/tu-d-207b-07-radiomic-response-assessment-for-recurrent-glioblastoma-treated-with-bevacizumab-in-the-brain-trial
#10
P Grossmann, V Narayan, R Huang, H Aerts
PURPOSE: To develop radiomic biomarkers for non-invasive response assessment of Bevacizumab (Avastin; Genentech) treatment in recurrent glioblastoma multiforme (GBM). METHODS: We analyzed prospectively acquired data from the BRAIN trial. For 167 patients, we extracted 71 radiomic features each from normalized post-contrast T1-weighted and fluid attenuation inversion recovery (FLAIR) sequences at baseline (pretreatment), and at follow-ups of six and twelve weeks (post-treatment), respectively, where available...
June 2016: Medical Physics
https://www.readbyqxmd.com/read/28035003/a-quininib-analogue-and-cysteinyl-leukotriene-receptor-antagonist-inhibits-vascular-endothelial-growth-factor-vegf-independent-angiogenesis-and-exerts-an-additive-antiangiogenic-response-with-bevacizumab
#11
Clare T Butler, Alison L Reynolds, Miriam Tosetto, Eugene T Dillon, Patrick J Guiry, Gerard Cagney, Jacintha O'Sullivan, Breandán N Kennedy
Excess blood vessel growth contributes to the pathology of metastatic cancers and age-related retinopathies. Despite development of improved treatments, these conditions are associated with high economic costs and drug resistance. Bevacizumab (Avastin®), a monoclonal antibody against vascular endothelial growth factor (VEGF), is used clinically to treat certain types of metastatic cancers. Unfortunately, many patients do not respond or inevitably become resistant to bevacizumab, highlighting the need for more effective antiangiogenic drugs with novel mechanisms of action...
March 3, 2017: Journal of Biological Chemistry
https://www.readbyqxmd.com/read/27999187/targeting-the-pro-angiogenic-forms-of-vegf-or-inhibiting-their-expression-as-anti-cancer-strategies
#12
Mélanie Guyot, Caroline Hilmi, Damien Ambrosetti, Marco Merlano, Cristiana Lo Nigro, Jérôme Durivault, Renaud Grépin, Gilles Pagès
Tumor growth relies on oxygen and blood supply depending on neo-vascularization. This process is mediated by the Vascular Endothelial Growth Factor (VEGF) in many tumors. This paradigm has led to the development of specific therapeutic approaches targeting VEGF or its receptors. Despite their promising effects, these strategies have not improved overall survival of patients suffering from different cancers compared to standard therapies. We hypothesized that the existence of anti-angiogenic forms of VEGF VEGFxxxb which are still present in many tumors limit the therapeutic effects of the anti-VEGF antibodies bevacizumab/Avastin (BVZ)...
February 7, 2017: Oncotarget
https://www.readbyqxmd.com/read/27996119/bevacizumab-chemotherapy-for-management-of-pulmonary-and-laryngotracheal-papillomatosis-in-a-child
#13
Karen B Zur, Elizabeth Fox
Recurrent laryngeal papillomatosis (RRP) can be a devastating condition for a child to endure, and pulmonary involvement may have terminal consequences. Adjuvant therapies have been trialed and reported over the years; however, these chemotherapy options have not been successful. Bevacizumab (Avastin, Genetech Inc., South San Francisco, CA) is a vascular endothelial factor (VEGF) inhibitor that has shown promise in the management of papillomatosis. Most research has focused on intralesional injections of this antiangiogenic drug...
December 20, 2016: Laryngoscope
https://www.readbyqxmd.com/read/27972449/a-budget-impact-analysis-to-estimate-the-economic-consequences-of-introducing-the-combination-of-avastin-tarceva-for-the-treatment-of-first-line-epidermal-growth-factor-egfr-metastatic-non-small-cell-lung-cancer-nsclc
#14
P Orfanos, E J Wright, V C Munk
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27930983/sargassum-fusiforme-polysaccharides-inhibit-vegf-a-related-angiogenesis-and-proliferation-of-lung-cancer-in-vitro-and-in-vivo
#15
Huiling Chen, Ling Zhang, Xiange Long, Peifei Li, Shengcan Chen, Wei Kuang, Junming Guo
Sargassum fusiforme (Harv.) is a brown alga belonging to the Sargasaceae family. The Sargassum fusiforme polysaccharides (SFPS) have demonstrated good anti-tumor and immunomodulatory activity. However, the underlying mechanisms of its anti-tumorigenesis, especially the anti-angiogenic activity is yet to be established. In the present study, we attempted to determine the effects of SFPS on the human lung adenocarcinoma SPC-A-1 cells and its xenograft model. The results showed that SFPS provides a concentration-dependent inhibition of SPC-A-1 cell proliferation in in vitro and the tumor growth in in vivo studies...
January 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/27928444/the-remote-effects-of-intravitreal-anti-vegf-therapy
#16
F Balta, M Merticariu, C Taban, G Neculau, A Merticariu, D Muresanu, D Badescu, V Jinga
Objective: To study the effects of intravitreal anti-Vascular Endothelial Growth Factor (VEGF) therapy with Avastin for wet Age-Related Macular Degeneration (AMD) on Benign Prostatic Hyperplasia (BPH)-related symptoms. Methods: An exploratory trial was conducted from August 1, 2013 to February 1, 2014, that included 14 male patients previously diagnosed with BPH, who were aged between 59 and 69 years. The trial was performed in Bucharest and involved two medical institutions: the Clinical Hospital of Eye Emergencies and the "Prof...
October 2016: Journal of Medicine and Life
https://www.readbyqxmd.com/read/27896177/anti-vascular-endothelial-growth-factor-bevacizumab-therapy-reduces-hypertrophic-scar-formation-in-a-rabbit-ear-wounding-model
#17
Do Hoon Kwak, Tae Hui Bae, Woo Seob Kim, Han Koo Kim
BACKGROUND: Hypertrophic scarring is a pathological condition that occurs after trauma or surgery. Angiogenesis occurs more often with hypertrophic scarring than with normotrophic scarring. The regulation of angiogenesis is one of the key factors in hypertrophic scar management. Vascular endothelial growth factor (VEGF) is an essential factor in the angiogenetic response. This study investigated whether decreasing the level of VEGF is effective for treating hypertrophic scarring. METHODS: Ten 8-week-old female New Zealand white rabbits were included...
November 2016: Archives of Plastic Surgery
https://www.readbyqxmd.com/read/27893676/combination-use-of-paclitaxel-and-avastin-enhances-treatment-effect-for-the-nsclc-patients-with-malignant-pleural-effusion
#18
Nan Qi, Fang Li, Xiaosong Li, Huanrong Kang, Hui Zhao, Nan Du
The current study is conducted to investigate efficacy of the chemotherapy drug paclitaxel in combination with Avastin (Roche Diagnostics GmbH., Mannheim, Germany) (antiangiogenic agent) in treatment of malignant pleural effusions (MPEs).Twenty-four patients with non-small cell lung cancer were randomly assigned for 2 treatment approaches. Ten patients received paclitaxel (175 mg/m) alone, and 14 patients took a combination therapy of paclitaxel and Avastin (5 mg/kg). Efficacy of the treatment approaches in the patients was validated with the change in the MPE volume...
November 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27882018/role-of-bevacizumab-in-the-prevention-of-early-postoperative-haemorrhage-after-25-gauge-microincision-vitrectomy-surgery
#19
Zaheer Sultan, Syed Fawad Rizvi, Faisal Murtaza Qureshi, Syed Asaad Mahmood
OBJECTIVE: To evaluate the effect of preoperative intravitreal bevacizumab injection on the incidence of postoperative haemorrhage and visual prognosis, in patients undergoing 25-gauge micro incision vitrectomy surgery (MIVS) for diabetic vitreous haemorrhage. METHODS: One hundred and twenty two eyes of 122 patients of diabetic retinopathy of both genders and aged over 18 years, who presented with non-resolving vitreous haemorrhage were enrolled for this study. All patients received an intravitreal injection of 1...
September 2016: Pakistan Journal of Medical Sciences Quarterly
https://www.readbyqxmd.com/read/27876365/midyear-commentary-on-trends-in-drug-delivery-and-clinical-translational-medicine-growth-in-biosimilar-complex-injectable-drug-formulation-products-within-evolving-collaborative-regulatory-interagency-fda-ftc-and-doj-practices-and-enforcement
#20
Rodney J Y Ho
Before the 2009 Biologics Price Competition and Innovation Act that enabled the U.S. Federal Drug Administration (FDA) to create the 351(k) Biologic License Application-an abbreviated biosimilar approval process, FDA approved follow-on biomolecule products such as beta-interferon, glucagon, hyaluronidase, and somatropin (human growth hormone) under varying and evolving rules. With the 351(k) Biologic License Application biosimilar approval process in place, currently, there are 4 (licensed in 2015-2016) biosimilars available, namely Neupogen (filgrastim; $1 B/y), Humira (adalumumab; $14...
February 2017: Journal of Pharmaceutical Sciences
keyword
keyword
1771
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"